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PENGETIPAN MOLEKUL Mycobacterium tuberculosis YANG BERKAIT 
DENGAN JANGKITAN TUBERKULOSIS LUARPULMONARI 
 
 
ABSTRAK 
Kemajuan terkini dalam pengetipan molekul menyediakan teknik-teknik yang 
mantap untuk menganalisis kepelbagaianstrain Mycobacterium tuberculosis dan juga 
pola transmisi jangkitan. Dalam kajian percubaan pertama dari Kelantan, Malaysia, 
kekerapan dan kepelbagaian M. tuberculosis genotip yang dikaitkan dengan 
tuberkulosis luar pulmonari (EPTB) telah dijalankan menggunakan teknik 
spoligotyping. Keputusan genotip dibandingkan dengan SITVIT Web, pangkalan 
penanda molekul data antarabangsa terbesar untuk M. tuberculosisyang 
mengandungi 7104 corak spoligo di seluruh dunia. Hasil kajian menunjukkan 
bahawa 74.6% (n = 44) daripada pencilan telah dikategorikan di bawah “ shared 
international type”(SIT) yang telah ditakrifkan sebelum ini manakala 25.4% (n = 15) 
yang tidak mempunyai nombor SIT telah dikategorikan sebagai strain “orphan”. 
Keturunan terbesar terdiri daripada 23 pencilan (38.9%) yang dimiliki oleh keturunan 
Beijing. Kajian ini mencadangkan kekerapan M. tuberculosis lebih berkait dengan 
tetapan geografi dan bukan pada tempat-tempat jangkitan. Satu bahagian strain yang 
berkaitan dengan EPTB dalam populasi kajian ini juga disebabkan oleh strain baru 
yang tidak terdapat dalam pangkalan data SITVIT Web itu. Kajian ini boleh 
berfungsi sebagai bahan rujukan bagi kajian pengetipan masa hadapan untuk 
penganggaran sebenar kelaziman M. tuberculosis yang berkaitan dengan EPTB di 
Malaysia amnya. 
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MOLECULAR GENOTYPING OF Mycobacterium tuberculosis ASSOCIATED 
WITH EXTRAPULMONARY TUBERCULOSIS 
 
 
ABSTRACT 
Recent advances in molecular typing provide a robust tool to analyse the 
heterogeneity of Mycobacterium tuberculosis strains as well as their transmission 
patterns. In the first attempt study from Kelantan, Malaysia, the frequency and 
diversity of M. tuberculosis genotypes associated with extrapulmonary tuberculosis 
(EPTB) were performed using spoligotyping. Genotyping results were compared 
with the SITVIT Web, a largest M. tuberculosis molecular markers international 
database containing 7104 spoligotype patterns worldwide. The results showed that 
74.6 % (n = 44) of the isolates were grouped under previously defined shared 
international type (SIT) numbers while 25.4 % (n = 15) did not have any SIT 
numbers, thus designated as orphan strains. The largest lineage comprised of 23 
isolates (38.9 %) belonging to the Beijing lineage. Present study suggested frequency 
of M. tuberculosis lineages are related more on geographical settings rather than sites 
of infection. Bulk of the strains associated with EPTB in the study population also 
caused by new strain that is not available in the SITVIT Web database. The study 
may serves as a reference material for further genotyping studies on estimating the 
actual prevalence of M. tuberculosis associated with EPTB in Malaysia generally. 
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CHAPTER 1: INTRODUCTION 
Tuberculosis (TB) remains as a major public health problem which has caused 
significant morbidity and mortality worldwide (WHO, 2014). This airborne disease 
is caused by Mycobacterium tuberculosis, the most common strain of mycobacteria 
that cause pulmonary TB (PTB) in human. It may also infect other parts of the body 
causing extrapulmonary TB (EPTB). 
1.1 History of tuberculosis        
For centuries long, TB has been known to a mankind as devastating plague. It was 
inferred to present as early as prehistory period of time and continued to kill people 
until today. Archaeological evidences had showed TB was present in Egypt more 
than 5000 years ago (Daniel, 2006). Typical skeletal abnormalities of TB which 
include Pott‟s deformities was found in Egyptian mummies and were clearly 
depicted in early Egyptian art. Similarly, archaeological evidence of early TB was 
also found in a Columbian prehispanic mummy (200 BC – AD 100) in Sinu River, 
Colombia demonstrating spinal TB (Palomino et al., 2007). In China and India, TB 
has been documented as early as 2300 and 3300 years ago, respectively.   
The much older name for TB originally came from the ancient Greek as phthisis 
which means consumption (Daniel, 2006). Hippocrates (460 – 377 BC), a Greek 
physician has recognized phthisis as the most widespread disease during the time. In 
his writing, he described it as a fatal disease that attacked people between the age 18 
and 35 years. Aristotle (384-322 BC) had considered TB as contagious disease 
though most of authors at that time believed it to be a hereditary disease or due to 
individual‟s mental and moral weaknesses. Clarissimus Galen (131-201 AD), the 
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most renowned physician after Hippocrates had suggested phthisis as ulceration of 
lungs, chest or throat that comes along with cough and low fever (Pease, 1940). 
The Great White Plaque marked the beginning of TB epidemic in Europe. It last for 
more than 200 years and probably started in early 17th century. Death was 
considered inevitable at that time and by 1650, TB was recognized as the leading 
cause of the mortality. It was deduced that the dissemination is due to high 
population density and poor sanitary in waxing cities of Europe and North America, 
provide crucial environment for the spread of the disease. The TB epidemic 
ultimately spread gradually to other countries through exploration, immigration and 
colonization (Daniel, 2006). Meanwhile, TB in Asia hit the highest point in China 
and India toward the end of 19
th
 century. 
Franciscus Sylvius (1614-1672) was the first to use the term tubercle to describe 
consistent lesions in lungs and other viscera of consumption patients that could 
progress to ulcers and cavities (Palomino et al., 2007). Later, Richard Morton (1637-
1698) confirmed tubercles were always present in patients of lung consumption and 
Laurent Bayle (1774-1816) had proved the tubercles were not a consumption product 
but rather the cause of the illness. In 1839, Johan Lukas Schonlein brought in the 
name „tuberculosis‟ to describe the disease replacing the words phthisis and 
consumption in TB history. On March 24, 1882, Robert Koch disclosed that he had 
identified and isolated the causative agent for TB, a rod-shaped bacterium known as 
tubercle bacillus to Berlin Physiological Society (Gradmann, 2006). 
Koch‟s postulates brought a new paradigm in TB era as it led to subsequent findings 
of tuberculin, a substance isolated from tubercle bacilli which is initially regarded as 
a TB cure. Although Koch failed to demonstrate it, his findings become a 
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cornerstone to create a diagnosis for TB. Clemens Freiherr vor Pirquet introduced a 
term “latent tuberculosis” in 1907 as he noted a positive reaction to tuberculin among 
child who did not manifested the disease (Gideon and Flynn, 2011). Subsequently, 
Charles Mantoux introduced a cannulated needle and syringe used to inject the 
tuberculin intracutaneously in 1908. During 1930s, Florence Serbeit established 
purified protein derivative (PPD), an active component of tuberculin for diagnosing 
TB that is still used until today (Daniel, 2006). 
Sanatorium regimen which started by Herman Brehmer (1826-1889) was the first 
broadly implementation of TB treatment throughout Europe and United States. The 
idea of the regimen was to protect the public by isolating ill person and help TB 
patients in healing process by providing them adequate bed rest, exercise, fresh air 
and good nutrition (McCarthy, 2001; Warren, 2006). This approach was then 
gradually replaced by the drug therapy. The discovery of streptomycin in 1934 
followed by para-aminosalicyclic acid, nicotinamide, conteben, isoniazid, rifampicin, 
pyrazinamide, ethambutol, cycloserine and ethuonamide gave a new hope in treating 
TB disease. In 1921, the BCG (Bacillus Calmette-Guerin) vaccine against TB 
developed by Albert Calmette (1863-1933) and Camille Guerin (1872-1961) was 
administered in human. The vaccine is still vastly applied until today (Daniel, 2006). 
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1.2 Etiologic agent of tuberculosis  
TB is usually caused by M. tuberculosis complex, a group of closely related species 
that shared 99.9 % similarity at nucleotide level and identical 16S rRNA gene 
sequences (Brosch et al., 2002; Whitman et al., 2012). Regardless of their genetic 
homology, each of the members is associated with specific primary host, although 
infection can also occur in various alternative hosts. M. tuberculosis complex 
members also differ in phenotypic characteristics. 
The group comprises M. tuberculosis, which is the main etiologic agent of human TB 
worldwide; Mycobacterium africanum, a common cause of human TB in West 
African countries (Mostowy et al., 2004); Mycobacterium bovis which 
predominantly causes bovine TB, yet can produce zoonotic TB in human          
(Kubica et al., 2006); Mycobacterium bovis BCG, a live attenuated strain vaccine 
that is used to immunize people against TB (Mahairas et al., 1996); Mycobacterium 
microti which typically causes TB in rodent, but have been reported to                 
cause infection in both immunocompromised and immunocompetent patients                  
(van Sooligen et al., 1998); Mycobacterium canetti, a smooth tubercle bacilli variant 
that was first isolated in 1969 from a native Frenchman (van Soolingen et al., 1997); 
Mycobacterium caprae, a causative agent of caprine TB that was firstly isolated from 
goat in Spain (Aranaz et al., 2003); Mycobacterium pinnipedii which primarily 
infects seals (Cousins et al., 2003) and Mycobacterium mungi, a TB causative agent 
in banded mongoose that were found to live near human population in Botswana 
(Alexander et al., 2010). In addition, another two distinct branches, dassie and oryx 
bacilli, which are found to have phylogenetic similarities yet are not completely 
described, were also included in the group (van Ingen et al., 2012). Dassie and orxy 
bacilli were primarily isolated from hyrax and bovidae family, respectively. 
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1.2.1 General characteristic of M. tuberculosis complex 
All members of M. tuberculosis complex are found to be aerobic, non-motile,        
non-sporulating and slow-grower (Warren & Body, 1995). The shaped are rod with 
straight to slightly curved, ranging in size from 0.2 – 0.6 x 1.0 – 10 µm. They are 
considered to be gram-positive organism due to lack of an outer cell membrane. 
Generally, morphological colonies of mycobacteria are being classified as either 
having a smooth and soft or rough and crumbly appearance (Lehman et al., 2007). 
The mycobacteria colonies colour is typically buff. For example, M. tuberculosis 
colonies are raised, non-pigmented and appear to be dry with rough appearance. The 
colonies often present with cording pattern, a curved strand of bacilli appearance 
resulting from tight cohesion of the bacilli.  
As for growth requirement, mycobacteria need a carbon source, a nitrogen source 
and essential metal ions such as iron, magnesium and zinc. Fatty acids have been 
found to stimulate the growth, yet high concentration can lead to inhibitory effect. 
The most important source for growth is oxygen. Some of the species are 
microaerophilic, which require oxygen but at lower level for instance M. bovis and 
M. africanum while M. tuberculosis is a strict aerobe (Niemann et al., 2000). 
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1.2.2  Overview of mycobabacteria cell envelope structure 
Generally, mycobacteria cell envelope encompasses a cytoplasmic membrane, a cell 
wall and a capsule-like outermost layer. The cytoplasmic membrane is a typical 
bilayer membrane and has thickness of approximately 4 to 4.5 nm.  It is surrounded 
by a unique cell wall that has high lipid content (Rom & Garay, 2004). Due to this 
property, the cell wall prevents accurate gram staining, allows only staining by acid-
fast dyes and is known as acid-fast organism.  
The mycobacteria cell wall is made up of peptidoglycan, arabinogalacatan and 
mycolic acids (MA). Peptidoglycan, the innermost layer confers rigidity to help 
mycobacteria maintain its shape (Hett & Rubin, 2008). It is linked to 
arabinogalactan, the major polysaccharide in cell wall constituents. The 
arabinogalactan in turns are covalently linked to MA, a long chain series of fatty 
acids that represent more than 50 % of cell wall mass. These MA are responsible for 
thick waxy lipid coat characteristic of mycobacteria which contributes to 
impermeability of the cell wall and virulence (Glickman et al., 2000; Kieser & 
Rubin, 2014). 
 The capsule-like outermost layer consists of lipids, glycolipids and proteins that vary 
between species and some, like lipomannan, lipoarabinomannan and cord factor are 
contributing to mycobacteria virulence (Brennan, 2003). Figure 1.1 shows a 
schematic illustration of the main components of mycobacteria cell envelope and 
their distribution. 
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Figure 1.1: The schematic illustration of mycobacterial cell envelope. (Adapted from 
Hett & Rubin, 2008). 
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1.2.3 Mycobacterial genome  
Mycobacteria genome is encoded in a single circular deoxyribonucleic acid (DNA) 
with high guanine and cytosine (G + C) content ranges from 64 % to 70 % of the 
genome. In 1998, a first complete genome sequence was elucidated for M. 
tuberculosis H37Rv, a virulent laboratory reference strain by Cole et al., (1998). It 
was revealed that the strain posses a high G + C content (65.5 %) with a genome size 
of 4 411 529 base pair (bp). Analysis of the genome revealed that the pathogen has 
all genes for essential catabolic and anabolic metabolic pathways in which a large 
fraction of the genes was found to be devoted to lipid and polypeptide metabolism 
(Saunders & McFadden, 2003).  
Comparative genomic studies between M. bovis BCG-Pasteur, an attenuated strain 
used for BCG vaccination had revealed absence of a few regions (region of 
difference, RD 1-14) in relative to M. tuberculosis H37Rv. According to Gordon et 
al., (1999), RD 1 until RD 3 were found to be specific deletion to M. bovis BCG 
while RD 4 until RD 7 were also found to be absence on M. bovis. It is postulated 
that amongst these specific deletion regions contributed to the attenuation of the live 
tuberculosis vaccine of M. bovis BCG (Pym et al., 2002). 
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1.3 Transmission of tuberculosis 
TB transmission occurs when a person inhale droplet nuclei containing                      
TB bacilli ranges from 1 to 5 µm in diameter. These droplet nuclei were generated 
when infected persons cough, sneeze, spit or shout. Depending on the environment, 
these tiny particles can remain suspended in air for several hours (CDC, 2008). Once 
inhaled, the droplets transverse the mouth, upper respiratory tract and bronchi before 
settle down in alveoli of the lungs. Figure 1.2 (a) illustrated the transmission of TB, 
spreading from person to person.  
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1.4 Pathogenesis of tuberculosis 
Infection occurs once TB bacilli deposited in alveoli, where they are surrounded and 
engulfed by alveolar macrophages. The bacilli continued to multiply in the 
macrophages, initiate a recruitment of inflammatory cells to the area, which in turns 
forming an early tubercle. In the meantime, dendritic cell presentation of tubercle 
bacilli antigens leads to T cell priming and trigger an adaptive immune response.    
The accumulation of activated macrophages, T cells, B cells and other host cells      
lead to the formation of the granuloma, which can contain the bacilli                        
(Nunes-Alves et al., 2014) as illustrated in Figure 1.2 (b). 
The granuloma formed limits the replication and spread of the bacilli. Destroyed 
macrophages released the bacilli and formed a caseous center in the lesion, restricted 
further growth of bacilli. The infection progression is halted, yet, some of them are 
able to survive in this deleterious condition and enter a dormancy state. Apart from 
that, the lesion may become calcified or continued to liquefy and eventually ruptured 
causing the bacilli to be released in neighbouring vessels and airways (Nunes-Alves 
et al., 2014). In this state, bacilli can be easily spread when the infected person 
cough, sneeze or speak. 
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Figure 1.2: Transmission (a) and pathogenesis (b) of TB infection. (Adapted from 
Nunes-Alveset al., 2014). 
 
 
 
 
 
 
 (a) 
(b) 
12 
 
1.5 Active tuberculosis 
A person who is infected with TB may not necessarily develop the disease. Most 
people developed adequate immunity to keep the infection at bay. In fact, healthy 
people who are infected with TB only have 5 % to 10% chance of converting to 
active disease over their lifetime (WHO, 2002).  
1.5.1 Pulmonary tuberculosis 
PTB is the most common clinical manifestation of active TB. Symptoms may include 
chest pain and prolonged cough that last for 3 weeks or longer, which may be 
accompanied with the present of blood or sputum. Shortness of breath usually 
indicates extensive TB disease with widespread involvement of lung and 
parenchyma (Rossman & MacGregor, 1995). According to previous study, about      
25 % of people may remain asymptomatic in the early stages of the disease (Lawn & 
Zumla, 2011).  
1.5.2 Extrapulmonary tuberculosis 
TB infection may spreads outside lung causing EPTB, representing about 15 % to     
20 % of all TB cases in immunocompetent patients (Sharma & Mohan, 2004). 
Though disseminated form may also occur, EPTB is usually confined to a single site.  
According to Betts et al., (2003), symptoms and signs are localized with minimal or 
absent constitutional symptoms. Those with constitutional symptoms, usually have 
more widespread disease or pulmonary involvement. 
Apart from that, the diagnosis of EPTB is often complicated due to atypical clinical 
manifestation, difficulty in obtaining specimens for laboratory confirmation and 
paucibacillary characteristic of the specimens (Sharma & Mohan, 2004; Norbis et al., 
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2014). Hence, only a few proportions of cases have positive microbiological 
confirmation for M. tuberculosis. Delayed presentation, inaccurate diagnosis and 
inappropriate treatment might worsen the scenario in EPTB cases.  
1.5.2 (a) Lymph node tuberculosis 
Lymph node TB is the most common form of EPTB, often involve cervical lymph 
nodes, with or without associated disease with other lymphoid tissue. Numerous 
studies have found that lymph node have predilection for women, approximately 2:1 
and is more common in younger patients (Thornton, 1995; Eshete et al., 2011). It 
usually presents with gradually increasing painless swelling lymph nodes of weeks to 
month duration. Some patients may have systemic symptoms.   
1.5.2 (b) Pleural tuberculosis 
Pleural TB occurs when ruptured subpleural infected foci of M. tuberculosis spread 
into pleural space (Thornton, 1995). Symptoms may include pleurisy, chest pain, 
cough and fever. A chest x-ray (CXR) often show a unilateral effusion with 
commonly small to moderate in size. Bilateral pleural TB effusions are rare and 
associated with disseminated disease. A person with pleural TB may have underlying 
pulmonary infection that is masked on CXR due to compression of effusion fluid to 
the lung. 
1.5.2 (c) Central nervous system tuberculosis 
Central nervous system (CNS) infection is the most devastating form of TB. It 
constitutes approximately 5 % to 15% of the EPTB cases, carries a high morbidity 
and mortality despite of given anti-TB treatment (Marais et al., 2010). According to 
Norris & Buckley (1995), in early stages of infection, tuberculous foci developed in 
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meninges, spinal cord or brain parenchyma following haematogenous seeding. Later, 
the foci ruptured into subarachnoid space manifest primarily as tuberculous 
meningitis and less commonly as tuberculous encephalitis, tuberculoma and brain 
abscess. 
1.5.2 (d) Skeletal tuberculosis 
Skeletal TB refers to TB infection of the bones and/or joints. It usually involves 
weight-bearing bones and joints such as spine, hip, knee, wrist and shoulder 
(Sankaran, 1993). Spine TB, often accompanied with back pain is the commonest 
form of skeletal TB. It was responsible for about 40 % to 50% of the cases      
(Agrawal et al., 2010). Prompt diagnosis is often difficult due to failure of consider 
TB in differential diagnosis.   
1.5.2 (e) Genitourinary tuberculosis 
Genitourinary TB commonly present only after a long latent period ranges from          
5 to 25 years. It often involves men more than women at nearly a 2:1 ratio            
(Rom & Garay, 2004).  Any part of genitourinary systems such as kidney, bladder, 
fallopian tube, prostate and epididymis may be involved. Patients may normally 
present with symptoms referred to organ involved or may have unexplained 
urological symptoms.  
1.5.2 (f) Abdominal tuberculosis 
Abdominal TB is defined as mycobacterial infection in the gastrointestinal tract, 
peritoneum, or intra-abdominal solid organs. According to Grange & Zumla (2008), 
abdominal TB can be acquired due to swallowed infected sputum of active PTB, 
haematogenous dissemination from a focus of active PTB or military TB or spread of 
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bacilli from infected adjacent organs. Symptoms and signs of infection are 
nonspecific, often lead to difficulty in diagnosis. They include weight loss, 
abdominal pain and tenderness, anorexia, diarrhoea, fever and night sweats.  
1.5.2 (g) Miliary tuberculosis 
Miliary TB refers to TB infection involving many different organs, including the 
lung. It occurs when tubercle bacilli enter the bloodstream and disseminate to all 
parts of the body, where they grow and cause disease in multiple sites (Thornton, 
1995). The term “miliary” refers to the radiograph appearance of millet seeds, 
usually less than 2 mm in diameter scattered throughout the lung. This condition is 
rare, accounts for 2 % from all TB cases, yet has high mortality rate despite of 
availability of effective TB treatment (Sharma et al., 2012). It is more common in 
older age groups and in human immunodeficiency virus infection/ acquired immune 
deficiency syndrome (HIV/AIDS) patients.  
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1.6 Latent tuberculosis 
People who are diagnosed having a latent TB infection do not feel sick and do not 
have any symptoms. Most of them are healthy with a normal chest x-ray and a 
negative sputum test. Generally, latent TB is defined solely on a positive result of 
particular tests namely tuberculin skin test (TST) and interferon-gamma release assay 
(IGRA) with the absence of clinical symptoms (National Clinical Guideline Centre, 
2006). People with latent TB are not infectious and cannot spread TB infections to 
others. However, they may develop to active TB diseases, often when their immune 
system becomes weak. 
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1.7 Epidemiology of tuberculosis 
TB disease remains a major public health threat worldwide. It is a second most 
common cause of death globally after HIV/AIDS. It was estimated 9 million of 
incidence cases corresponding to 126 cases per 100 000 population and 1.5 million 
of TB death globally in year 2013 (WHO, 2014). Yet, the newly infected cases were 
observed to be decreased 0.6 % between 2012 and 2013 while mortality rate has 
decreased 45 % since 1990.  
Out of 9.0 million of people that newly fell ill with TB, 1.1 million were co-infected 
with HIV. The occurrence was highest in African region with estimation of 34 % 
from the total TB cases locally. These cases represented 78 % of the TB cases co-
infected with HIV globally. Apart from that, 3.5 % of new TB cases and 20.5 % of 
previously treated cases are estimated to have multidrug resistance TB (MDR-TB). 
Overall, 9 % of these MDR-TB cases were reported to be extensive multidrug 
resistance TB (XDR-TB). It has been reported in 100 countries with most of them 
were notified from Ukraine, South Africa, India and Kazakhstan (WHO, 2014). 
Most of the TB cases were found in Asia, 56 % and African Region, 29 %. Small 
proportion of the cases occurred in Eastern Mediterranean Region, 8 % followed by 
European Region, 4 % and Region of America, 3 %. India and China alone had 
contributed 24 % and 11 % of global cases respectively. 82 % of incidence cases 
majorly were reported from high-burden countries while the lowest incidence rates 
were observed to be predominantly in high-income countries such as United State, 
Canada and Japan. Figure 1.3 showed world map distribution of estimated TB 
incidence rate for year 2013 (WHO, 2014). 
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Figure 1.3: Estimated TB incidence rates in 2013. (Adapted from WHO, 2014). 
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1.8 Factor affecting tuberculosis 
There are a number of risk factors for TB reported in former studies. It relies upon 
both the risk of being infected, depending on the incidence of TB in particular 
populations and the risk of infection leading to active disease, depending on many 
factors affecting on the individual genetically and environmentally. 
1.8.1 Human Immunodeficiency Virus 
HIV infection has resulted in increasing numbers of TB cases and TB mortality in 
many countries especially in populations with high HIV prevalence (D‟Ambrosio et 
al., 2012).  People living with HIV are estimated to develop TB 29 times greater than 
those who are HIV negative. Co-infection with HIV may cause increment in TB 
progression following primary infection, re-infection of TB or reactivation of latent 
TB infection. The extrapulmonary involvement can be seen in more than 50 % of TB 
and HIV co-infected patients while only 12 % to 20 % for immunocompetents 
patients. Development of TB in turns accelerates HIV replication led to more rapid 
progression of HIV disease. The co-infection act synergistically to magnify the 
burden of the diseases which ultimately causes death (Kwon and Ernst, 2011).  
1.8.2 Diabetes mellitus  
Globally, about 10 % of TB cases are linked to DM, a chronic metabolic disorder 
that weakens body immune systems. It is reported that people with DM have 2 to 3 
times higher risk on developing TB than non-diabetic people. DM may worsen TB 
patients‟ outcome as it can alter the immune system responses necessary to control 
TB infection and reduce bactericidal activity by interfering TB drugs 
pharmacokinetic (Jeon et al., 2012). Apart from that, patient might confront a greater 
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probability death during TB therapy due to DM implications, such as renal failure 
heart disease and renal impairment. 
1.8.3 Immigration 
A proportion of TB cases among immigrants population are steadily increased in 
many countries, for example United State and Europe. It is postulated that 
immigration portrays a critical role in spreading TB disease due to existing TB 
infection or reactivation of latent TB (Gilbert et al., 2009). The immigrants are 
usually poor workers that come from high TB burden countries and carry the 
infection with them. Majority of them live in overcrowded places, suffer from 
malnutrition and have limited access in healthcare system. These conditions are 
favourable for developing active TB, initiates a local transmission of the disease 
(Barnett & Walker, 2008). 
1.8.4 Smoking 
A strong relationship has been demonstrated in previous studies between TB and 
smoking. Reasons for the relationship may be explained by the adverse effects of 
smoking on pulmonary host defences causing smokers inefficiently combat TB 
infection (Wen et al., 2010). Smoking also reduces the effectiveness of TB therapy, 
which in turns prolonged the infection that may lead to severe TB forms. Active 
smokers are more likely to develop latent TB infection, progress to active TB and 
increase the risk of death than non-smokers. In addition, current population-based 
study in Taiwan has found smoking of more than 10 cigarettes a day for continuous 
period had a higher risk of TB recurrence (Yen et al., 2014). 
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1.8.5 Malnutrition 
Association between TB and malnutrition is known for a long time. It has been 
reported malnutrition profoundly affects cell mediated immunity which play a major 
role in body defense against TB (Cegielski & McMurray, 2004). Altered immunity, 
by this means increases the burden of primary infection or initiate latent TB 
progression to active TB. These malnourished active TB patients tend to have 
delayed recovery and higher mortality compared to well-nourished patients. 
1.8.6 Poverty 
TB is often known as a disease of poverty. Prevalence of TB is noted to be higher in 
poor countries with the lowest national products particularly in Sub-Saharan African 
regions (Palomino et al., 2007). In comparison to wealthy countries, poor countries 
are lacking a good public health care system which is expected to keep TB endemic 
under control. Apart from that, poor people might live in unfavourable conditions 
that increase TB infection susceptibility and spreading of the disease, for instance, 
crowded living condition, lack of sanitary and poor nutrition. 
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1.9 Tuberculosis in Malaysia 
TB is one of the top five communicable diseases in Malaysia. In 1961, National 
Tuberculosis Control Programme was conducted with the aim to control morbidity 
and mortality causes by the disease. As a result, a significance number of reported 
TB cases had reduced from 350 cases per 100 000 population to less than 100 cases 
per 100 000 population in 1980‟s (Ministry of Health, 2011a). 
Generally, about two thirds of the TB patients in Malaysia were between 15 to 54 
years age group with male predominant. Small percentages of TB cases were also 
found among immigrants, whom usually came from high TB burden neighbouring 
countries (Iyawoo, 2004). Influx of the immigrants was noted to influence the 
number of TB cases particularly in several states in Malaysia. According to          
Dony et al., (2004), immigrants contributed more than 24 % of the incidence cases in 
Sabah. Currently, the highest number of TB cases was found to be in Sabah with 
4426 cases. Figure 1.4 shown the number of TB cases by Malaysia‟s states in 2012. 
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Figure 1.4: Number of TB cases according to Malaysia‟s states in 2012.        
(Adapted from Department of Statistic, 2013). 
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In the past few years, TB incidence rate in Malaysia was noticed to be gradually 
increased. As shown in Figure 1.5, increment of the incidence rate began in 2008 
with 77 per 100 000 populations and continue to increase until 99 per 100 000 
populations in 2013. In spite of that, TB mortality rate among HIV-negative patients 
remained constant with 5.8 per 100000 population for those years (WHO, 2014). 
A total of 24071 TB cases which has been notified in 2013 encompasses 23417 (97.3 
%) of new and relapse cases and 654 (2.7 %) of previously treated cases. Of the total 
number new and relapse cases, 14317 (61.1 %) cases were found to be pulmonary 
bacteriological confirmed and 5947 (25.4%) cases were pulmonary clinically 
diagnosed. EPTB cases were found to be 13.5 % (3153 cases) of the total TB cases 
(WHO, 2014). 
 
Figure 1.5: TB incidence rate per 100 000 populations in Malaysia, 2002-2013 
(Adapted from WHO, 2014) 
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